logo
Plus   Neg
Share
Email

J. C. Penney Q1 Loss Widens, Results Miss Estimates - Quick Facts

J. C. Penney Co., Inc. (JCP) reported Monday a first-quarter net loss of $154 million, or $0.48 per share, wider than a net loss of $78 million, or $0.25 per share in the prior-year quarter.

Excluding items, adjusted net loss for the quarter was $147 million, or $0.46 per share, compared to an adjusted net loss of $69 million, or $0.22 per share in the year-ago quarter.

Total net sales for the quarter decreased 5.6 percent to $2.44 billion from last year's $2.58 billion. Comparable sales decreased 5.5 percent for the quarter. The exit of the major appliances and in-store furniture categories had a combined negative impact of 20 basis points to comparable sales in the quarter.

On average, analysts polled by Thomson Reuters expected the company to report a loss of $0.38 per share on sales of $2.56 billion for the quarter. Analysts' estimates typically exclude special items.

The company said as its inventory rationalization effort continues, it is testing a number of strategies around optimal inventory levels and assortment choice counts with a goal of delivering an improved experience for its customers and maximizing its return on investment.

The Company adopted the provisions of the new Lease Accounting Standard starting in the first quarter of fiscal 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions. McDonald's is adding renewable energy to the grid, as part of its efforts to address climate change. The fast-food giant said it signed two long-term, large-scale virtual power purchase agreements or VPPAs to buy renewable energy generated by wind and solar power. Under the agreements, McDonald's will buy a combined 380MW in renewable energy.
Follow RTT
>